Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and Sequestered Naltrexone, in Patients with Chronic, Moderate to Severe Pain Lynn R. Webster, MD, Randall Brewer, MD, Chao Wang, PhD, Doreen Sekora, MPH, Franklin K. Johnson, MS, David Morris, PhD, Joseph Stauffer, DO, MBA Journal of Pain and Symptom Management Volume 40, Issue 5, Pages 734-746 (November 2010) DOI: 10.1016/j.jpainsymman.2010.05.004 Copyright © 2010 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 1 Patient disposition. Journal of Pain and Symptom Management 2010 40, 734-746DOI: (10.1016/j.jpainsymman.2010.05.004) Copyright © 2010 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 2 Mean percent change from baseline in average, worst, least, and current pain over duration of study for (a) ITT and (b) completer populations. aIncludes 2 patients who did not complete the study but provided assessments at week 52 visit. Journal of Pain and Symptom Management 2010 40, 734-746DOI: (10.1016/j.jpainsymman.2010.05.004) Copyright © 2010 U.S. Cancer Pain Relief Committee Terms and Conditions
Fig. 3 Mean (standard error of the mean) plasma morphine concentrations over duration of study (patients in PK substudy [n=93]). Journal of Pain and Symptom Management 2010 40, 734-746DOI: (10.1016/j.jpainsymman.2010.05.004) Copyright © 2010 U.S. Cancer Pain Relief Committee Terms and Conditions